{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-041486","form_type":"8-K","ticker":null,"cik":"0001840574","company_name":"Verve Therapeutics, Inc.","filed_at":"2023-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.039554+00:00","generated_at":"2026-06-19T08:17:31.052148+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Verve Therapeutics amends bylaws to align with universal proxy rules","bullets":["Board approved Second Amended and Restated Bylaws effective February 14, 2023.","Eliminates requirement to provide stockholder list during meetings; adds adjournment for technical failures.","Enhances nomination procedures: requires disclosure and 67% voting power solicitation under Rule 14a-19.","Non-compliant nominations will be disregarded; proxies or votes for such nominees not counted.","Includes technical, conforming, and clarifying changes."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-041486","json":"https://secwatch.observer/filing/0001193125-23-041486.json","markdown":"https://secwatch.observer/filing/0001193125-23-041486.md","text":"https://secwatch.observer/filing/0001193125-23-041486.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840574/000119312523041486/0001193125-23-041486-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840574/000119312523041486/d447068d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T08:17:31.052148+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"13e2702d3ce5c89f3b59bf0602f5d03d515c1935","claim":"Verve Therapeutics, Inc.: Amendment and restatement of bylaws eliminating stockholder list requirement during meetings, addressing remote meeting adjournment due to technical failure, and revising procedural mechanics for stockholder nominations and proposals under universal proxy rules (effective 2023-02-14).","evidence_excerpt":"On February 14, 2023, the board of directors (the “Board”) of Verve Therapeutics, Inc. (the “Company”) approved an amendment and restatement of the Company’s Amended and Restated Bylaws (as so amended and restated, the “Second Amended and Restated Bylaws”), effective immediately.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840574/000119312523041486/0001193125-23-041486-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-02-14"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}